Lutetium-PSMA-617 and Novel Agents in Prostate Cancer
Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Case 3: Metastatic Castrate-Resistant Prostate Cancer
Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Therapy Sequencing and Patient Selection in Prostate Cancer Treatment
Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.
mCRPC: The TheraP Trial
A review of recent data from the TheraP trial.
Reviewing Data from the CARD Trial
Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.
Case 2: Metastatic Hormone-Sensitive Prostate Cancer
Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.
Radium-223 and the ALSYMPCA Trial
A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.
Lutetium-PSMA-617 for Prostate Cancer Treatment
A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.
PSMA-Positive mCRPC and the VISION Trial
Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.
Case 1: Metastatic Castrate-Resistant Prostate Cancer
Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Defining PSMA-PET Scans for Prostate Cancer
Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.
Initial Risk Stratification of Localized Prostate Cancer
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
EP. 2B: New Horizons in Nuclear Medicine for Prostate Cancer
In an interview with Targeted Oncology™, Phillip J. Koo, MD, discusses both the role of novel PSMA tracers in prostate cancer imaging and the promise that theranostics, including LuPSMA, hold for prostate cancer therapy.
EP. 2A: The Role of Nuclear Imaging (PET) and PSMA in Prostate Cancer Therapy
In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.
2 Clarke Drive Cranbury, NJ 08512